1Dinger JC, Heinemann LA, Klihl - Hafaich D. The safety of adrospirenone - containing oral contraceptive : final results from theEuropean Active Survillance study on oral contraceptives based on142 475 women - years of observation[ J]. Contraception,2007,75(5) : 344-354.
2Seeger JD,Lou^ilin J,Eng PM, et al. Risk of thromboembolism inwomen taking Ethinylestradiol/ drospirenone and other oralcontraceptives[ J] . Contraception, 2007,110(3 ) : 587 -593.
3Parkin L, Sharpies K, Hernandez RK, et al. Risk of venousthromboembolism drospirenone or levonorgestrel : nested case -control study based on UK General Practice Research Database[ J].BMJ,2011, 340: d2139.
4Jick SS, Hemades RK. Risk of non - fetal venous thromboembolismin women using oral contraceptives containing drospirenonecompared with women using oral contraceptives containiglevonorgestrel : case - control using United States claims data [ J ].BMJ, 2011,340:d2151.
5Gadducci A, Barsotti C, Cosio S, et al. Smoking habit, immunesuppression,oral contraceptive use,and hormone replacementtherapy use and cervical carcinogenesis : a review of the literature[J]. Gynecol Endocrinol, 2011, 27(8) : 597 -604.
6Sayed GH,Zakherah MS, El - Nashar SA, et al. A randomizedclinical trial of a levonorgestel - releasing intrauterine system andalow 一 dose combined oral contraceptive for fibroid - relatedmenorrhagia[ J]. Int J Gynecol Obsted, 2011, 112(2) : 126 - 130.
7Bahamondes L, Monteiro 一 Dantas, Espejo - Arce X,et al. Aprospective study of the forearm bone density of users ofetonorgestrel — and levonorgestreal - releasing contraceptiveimplants[ J]. Hum Reprod, 2006 , 21(2) ; 466 -470.
8Monteiro - Dantas C, Espejo - Arce X,Lui - Filho, et al. Athree-years longitudinal evaluation of the forearm bone density ofusers of etonogestrel - and levonorgestrel - releasing contraceptiveimplants[ J]. Reprod Health,2007,4:11.
9Pongsatha S, Ekmahachai M, Suntomlimsiri N, et al. Bonemineral density in women using the subdermaJ contraceptiveimplant Implanon for at least 2 years[ J]. Int J Gynaecol Obstet,2010,109(3) : 223 -225.
10HarelZ, Wolter K, Gold MA, et al. Biopsychosocial variablesassociated with substantial bone mineral density loss during the useof depot medroxyprogesterone acetate in adolescents : adolescentswho lost 5% or more from baseline vs. those who lost less than 5%[J]. Contraception, 2010, 82(6) : 503 -512.
